PATENT CLAIM ANALYSIS

Application Number: 15961681
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-01
Patent Classification: ["514", "007200"]

Abstract:
The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.

Claim (Index 1):
A method of improving glycemic control in a patient with untreated type 2 diabetes mellitus comprising:\n administering once daily to the patient a therapeutically effective amount of desPro 36 Exendin-4(1-39)-Lys 6 -NH 2  (\u201clixisenatide\u201d) and/or a pharmaceutically acceptable salt thereof; wherein the improvement of glycemic control in the patient leads to a significant reduction of fasting plasma glucose (FPG) (mmol/L).

Metadata:
- Claim Count in Document: 20.0
- Percentile: 91.0
- Lexical Diversity: 1.59375
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13467757', '15237285', '13467707', '14781857', '15073364']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6280914684073364
- 35 USC 102 Novelty (BERT): 0.5517499733561485
- Combined Prediction Score: 0.6204573189022177
- Mean Citation Score: 364.889454
- Max Citation Score: 420.30463
- Similarity Product: 323.83905744230566

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test